1,2,3,4-四氢异喹啉-5-甲腈盐酸盐 | 1165924-13-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 中文名称: 1,2,3,4-四氢异喹啉-5-甲腈盐酸盐
• 英文名称: 1,2,3,4-tetrahydro-5-isoquinolinecarbonitrile hydrochloride
• 英文别名: 1,2,3,4-tetrahydroisoquinoine-5-carbonitrile hydrochloride；1,2,3,4-tetrahydroisoquinoline-5-carbonitrile hydrochloride；1,2,3,4-tetrahydroisoquinoline-5-carbonitrile;hydrochloride
• CAS: 1165924-13-9
• 化学式: C₁₀H₁₀N₂*ClH
• mdl: MFCD08752233
• 分子量: 194.664
• InChiKey: KOOYRALKUWAOGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.43
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.8
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2,3,4-四氢异喹啉-5-甲腈盐酸盐 在 盐酸 、 4-二甲氨基吡啶 、 盐酸羟胺 、 碳酸氢钠 、 caesium carbonate 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 126.08h， 生成 ethyl [5-(5-{3-cyano-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-3,4-dihydro-2(1H)-isoquinolinyl]acetate formate
  参考文献：
  名称：

  Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

  摘要：

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

  DOI：

  10.1021/jm5010336
• 作为产物：
  描述：

  tert-butyl 5-cyano-3,4-dihydro-2(1H)-isoquinolinecarboxylate 在 盐酸 作用下， 以 水 为溶剂， 反应 1.0h， 以71%的产率得到1,2,3,4-四氢异喹啉-5-甲腈盐酸盐
  参考文献：
  名称：

  WO2009/1128

  摘要：

  公开号：

文献信息

• [EN] OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P)<br/>[FR] DÉRIVÉS D'OXADIAZOLE ACTIFS SUR LA SPHINGOSINE-1-PHOSPHATE (S1P)
  申请人：GLAXO GROUP LTD

  公开号：WO2009080724A1

  公开（公告）日：2009-07-02

  The present application discloses oxadiazote based compounds of Formula (I) active on sphingosine-1-phosphate (S1P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heleroaryl ring; B is selected from one of the following; Formulae: (a) (b) (c)

  本申请公开了一种基于噁二唑酮的化合物，其化学式为（I），对神经酰胺-1-磷酸酯（S1P）具有活性，特别适用于治疗红斑狼疮。其中，A为苯基或5或6元杂环芳基环；B从以下化合物中选择一个：化学式：（a）（b）（c）。
• [EN] OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)<br/>[FR] DÉRIVÉS D'OXADIAZOLE ACTIFS SUR LA SPHINGOSINE-1-PHOSPHATE (S1P)
  申请人：GLAXO GROUP LTD

  公开号：WO2009080728A1

  公开（公告）日：2009-07-02

  The present application discloses oxadiazole based compounds of Formula (I) active o sphingosine-1-phosphate (S1 P) in particular useful to treat lupus erythematosus. A is phenyl or a 5 or 6-membered heteroaryl ring; B is selected from one of the following; Formulae: (a) (b) (c)

  本申请披露了一种基于噁二唑的化合物，其化学式为（I），活性为鞘氨醇-1-磷酸（S1P），特别适用于治疗红斑狼疮。其中，A为苯基或5或6元杂环芳基环；B从以下式中选取：(a)、(b)、(c)。
• OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1P)
  申请人：Heer Jag Paul

  公开号：US20100152235A1

  公开（公告）日：2010-06-17

  The present invention relates to a novel oxadiazole derivative having pharmacological activity, processes for its preparation, pharmaceutical compositions containing it and its use in the treatment of various disorders.

  本发明涉及一种具有药理活性的新型噁二唑衍生物，其制备过程、含有该衍生物的制药组合物以及其在治疗各种疾病中的应用。
• OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (S1p)
  申请人：Heer Jag Paul

  公开号：US20100273827A1

  公开（公告）日：2010-10-28

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁唑烷衍生物，其制备方法，含有它们的制药组合物以及它们在治疗各种疾病方面的应用。
• OXADIAZOLE DERIVATIVES ACTIVE ON SPHINGOSINE-1-PHOSPHATE (SIP)
  申请人：Heer Jag Paul

  公开号：US20100298373A1

  公开（公告）日：2010-11-25

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁唑烷衍生物，其制备方法，包含它们的制药组合物以及它们在治疗各种疾病方面的应用。